Clinical Trial

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Name: SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers — clinical trial record (NCT07080619)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-07-20.

Trial Details

NCT Number	NCT07080619
Lead Sponsor	Tianjin ConjuStar Biologics Co., Ltd.
Conditions	TNBC - Triple-Negative Breast Cancer, HR+ Breast Cancer
Enrollment	120 participants
Start Date	2025-09-20
Primary Completion	2027-07-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-11